Cargando…
Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study
Since the influenza season 2018/19, the Italian Ministry of Health recommended a dose of cell-based quadrivalent vaccine (Flucelvax Tetra) for HCWs (healthcare workers), because this vaccine seemed more efficacious in the prevention of AH3N2 virus. Due to the lack of pre-registration data, the safet...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147936/ https://www.ncbi.nlm.nih.gov/pubmed/34064483 http://dx.doi.org/10.3390/vaccines9050456 |
_version_ | 1783697739277664256 |
---|---|
author | Stefanizzi, Pasquale De Nitto, Sara Spinelli, Giuseppe Lattanzio, Sabrina Stella, Paolo Ancona, Domenica Dell’Aera, Maria Padovano, Margherita Soldano, Savino Tafuri, Silvio Bianchi, Francesco Paolo |
author_facet | Stefanizzi, Pasquale De Nitto, Sara Spinelli, Giuseppe Lattanzio, Sabrina Stella, Paolo Ancona, Domenica Dell’Aera, Maria Padovano, Margherita Soldano, Savino Tafuri, Silvio Bianchi, Francesco Paolo |
author_sort | Stefanizzi, Pasquale |
collection | PubMed |
description | Since the influenza season 2018/19, the Italian Ministry of Health recommended a dose of cell-based quadrivalent vaccine (Flucelvax Tetra) for HCWs (healthcare workers), because this vaccine seemed more efficacious in the prevention of AH3N2 virus. Due to the lack of pre-registration data, the safety profile of this new vaccine must be investigated in post-marketing surveillance. The aim of our study is to evaluate, through a post-marketing active surveillance program developed during the 2019/20 influenza season, any Adverse Events Following Immunization (AEFIs) that happened in the 7 days after immunization with Flucelvax Tetra. The study was carried out in a sample of HCWs of Policlinico General University-Hospital (Apulia, South Italy). AEFIs were classified as ‘serious’ or ‘not serious’ according to the WHO (World Health Organization) guidelines; the WHO causality assessment algorithm was applied to classify serious AEFIs. A total of 741 HCWs were enrolled, and 430 AEFIs (reporting rate: 58.0 (95%CI: 54.4–61.6) × 100 enrolled) were recorded. Of these, 429 of 430 (99.8%; reporting rate: 57.8 (95%CI: 54.2–61.5) × 100 enrolled) were classified as not serious and one (0.2%; reporting rate: 0.13 (0.03–0.75) × 100 enrolled) was classified as serious. Local reactions were the adverse reaction reported most frequently (88%); regarding the serious AEFI, causality assessment excluded the causal link with the administration of the vaccine. All the AEFIs resolved without sequelae. Flucelvax Tetra showed a profile of high safety. Due to their characteristics of greater sensitivity than passive surveillance, active surveillance programs can be useful in defining the safety profiles of a given vaccine/drug in certain population subgroups. |
format | Online Article Text |
id | pubmed-8147936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81479362021-05-26 Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study Stefanizzi, Pasquale De Nitto, Sara Spinelli, Giuseppe Lattanzio, Sabrina Stella, Paolo Ancona, Domenica Dell’Aera, Maria Padovano, Margherita Soldano, Savino Tafuri, Silvio Bianchi, Francesco Paolo Vaccines (Basel) Article Since the influenza season 2018/19, the Italian Ministry of Health recommended a dose of cell-based quadrivalent vaccine (Flucelvax Tetra) for HCWs (healthcare workers), because this vaccine seemed more efficacious in the prevention of AH3N2 virus. Due to the lack of pre-registration data, the safety profile of this new vaccine must be investigated in post-marketing surveillance. The aim of our study is to evaluate, through a post-marketing active surveillance program developed during the 2019/20 influenza season, any Adverse Events Following Immunization (AEFIs) that happened in the 7 days after immunization with Flucelvax Tetra. The study was carried out in a sample of HCWs of Policlinico General University-Hospital (Apulia, South Italy). AEFIs were classified as ‘serious’ or ‘not serious’ according to the WHO (World Health Organization) guidelines; the WHO causality assessment algorithm was applied to classify serious AEFIs. A total of 741 HCWs were enrolled, and 430 AEFIs (reporting rate: 58.0 (95%CI: 54.4–61.6) × 100 enrolled) were recorded. Of these, 429 of 430 (99.8%; reporting rate: 57.8 (95%CI: 54.2–61.5) × 100 enrolled) were classified as not serious and one (0.2%; reporting rate: 0.13 (0.03–0.75) × 100 enrolled) was classified as serious. Local reactions were the adverse reaction reported most frequently (88%); regarding the serious AEFI, causality assessment excluded the causal link with the administration of the vaccine. All the AEFIs resolved without sequelae. Flucelvax Tetra showed a profile of high safety. Due to their characteristics of greater sensitivity than passive surveillance, active surveillance programs can be useful in defining the safety profiles of a given vaccine/drug in certain population subgroups. MDPI 2021-05-04 /pmc/articles/PMC8147936/ /pubmed/34064483 http://dx.doi.org/10.3390/vaccines9050456 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stefanizzi, Pasquale De Nitto, Sara Spinelli, Giuseppe Lattanzio, Sabrina Stella, Paolo Ancona, Domenica Dell’Aera, Maria Padovano, Margherita Soldano, Savino Tafuri, Silvio Bianchi, Francesco Paolo Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study |
title | Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study |
title_full | Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study |
title_fullStr | Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study |
title_full_unstemmed | Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study |
title_short | Post-Marketing Active Surveillance of Adverse Reactions Following Influenza Cell-Based Quadrivalent Vaccine: An Italian Prospective Observational Study |
title_sort | post-marketing active surveillance of adverse reactions following influenza cell-based quadrivalent vaccine: an italian prospective observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147936/ https://www.ncbi.nlm.nih.gov/pubmed/34064483 http://dx.doi.org/10.3390/vaccines9050456 |
work_keys_str_mv | AT stefanizzipasquale postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT denittosara postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT spinelligiuseppe postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT lattanziosabrina postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT stellapaolo postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT anconadomenica postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT dellaeramaria postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT padovanomargherita postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT soldanosavino postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT tafurisilvio postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy AT bianchifrancescopaolo postmarketingactivesurveillanceofadversereactionsfollowinginfluenzacellbasedquadrivalentvaccineanitalianprospectiveobservationalstudy |